In this episode of the ‘AI in Business’ podcast, Scott Bradley, VP of AI and Innovation at Novartis, returns to discuss how AI is reshaping decision-making at the earliest stages of drug development—and what that means for the future of pharma investment strategy. Host Matthew DeMello and Scott explore how the pharmaceutical industry is transitioning from intuition-led portfolio choices to data-driven precision. They discuss the growing influence of AI in identifying viable drug candidates, designing complex proteins, and even solving long-standing manufacturing challenges. Scott also highlights the impact of AI on shifting portfolio dynamics—enabling pharma companies to target smaller, more specific patient populations and scale up development across a wider range of therapies. With AI now central to everything from molecule discovery to commercialization, the conversation offers a window into how life sciences organizations must adapt both structurally and strategically to stay competitive. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business’ podcast! This episode is sponsored by Intelligencia AI. Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1.
